Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2024; 84(06): 529-540
DOI: 10.1055/a-2300-5326
GebFra Science
Review/Übersicht

Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Article in several languages: English | deutsch
Rachel Würstlein
1   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Hans-Christian Kolberg
2   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Andreas D. Hartkopf
3   Department of Gynecology and Obstetrics, Tübingen University Hospital, Tübingen, Germany
,
Tanja N. Fehm
4   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf) Germany
,
Manfred Welslau
5   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Florian Schütz
6   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Peter A. Fasching
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Wolfgang Janni
8   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Isabell Witzel
9   Universitätsspital Zürich, Klinik für Gynäkologie, Zürich, Switzerland
,
Christoph Thomssen
10   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Annika Krückel
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Erik Belleville
11   ClinSol GmbH & Co. KG, Würzburg, Germany
,
Diana Lüftner
12   Immanuel Hospital Märkische Schweiz, Buckow, Germany & Medical University of Brandenburg Theodor-Fontane, Rüdersdorf, Germany
,
Michael Untch
13   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Marc Thill
14   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Manuel Hörner
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Hans Tesch
15   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
,
Nina Ditsch
16   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Michael P. Lux
17   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
,
Bahriye Aktas
18   Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
,
Maggie Banys-Paluchowski
19   Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
,
Florin-Andrei Taran
20   Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany
,
Achim Wöckel
21   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Nadia Harbeck
1   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Elmar Stickeler
22   Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany
,
Rupert Bartsch
23   Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria
,
Andreas Schneeweiss
24   National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Johannes Ettl
25   Klinikum Kempten, Klinikverbund Allgäu, Klinik für Frauenheilkunde und Gynäkologie, Kempten, Germany
,
David Krug
26   Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Strahlentherapie, Kiel, Germany
,
Volkmar Müller
27   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Clinical evidence is interpreted based on clinical studies and personal experience which can lead to different interpretations of data. This makes the opinions issued by panels of experts such as the Advanced Breast Cancer Panel which convened in November 2023 for the seventh time (ABC7) particularly important. At the conference, current issues around advanced breast cancer were evaluated by an international team of experts.

In 2023 the data on CDK4/6 inhibitors was so extensive that the answers to questions about the sequencing of therapy and the potential use of chemotherapy as an alternative therapy were relatively clear. Moreover, data on antibody drug conjugates which provides a good overview of their uses is available for all molecular subtypes.

Some therapeutic settings, including patients with brain metastases or leptomeningeal disease, older patients, locally advanced breast cancer and visceral crises, continue to be particularly important and were discussed in structured sessions. The scientific context of some of the topics discussed at ABC7 is presented and assessed here.

Keywords

breast cancer - metastatic - endocrine therapy - antibody drug conjugate - chemotherapy

Supplement

    • Supplement Tab. S1: Panelists of ABC7 conference.

    • Supplement Tab. S2: Questions voted on by the ABC7 panelists. Because voting was done live, the list does not claim to be complete. The questions have been numbered to match the text of this article. The numbering was not specified during the ABC7 conference.

  • Supporting Information

Supplement

    • Supplement Tab. S1: Panelisten der ABC7-Konferenz.

    • Supplement Tab. S2: Fragen der Abstimmung unter den ABC7-Panelisten. Wegen des Live-Charakters der Abstimmungen besteht kein Anspruch auf Vollständigkeit. Die Fragen sind nummeriert zum Text dieses Artikels. Die Nummerierung war keine Vorgabe der ABC7-Konferenz.

  • Supporting Information


Publication History

Received: 03 April 2024

Accepted after revision: 04 April 2024

Article published online:
29 May 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Diéras V, Miles D, Verma S. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 732-742
    CrossrefPubMedGoogle Scholar
  • 2 Verma S, Miles D, Gianni L. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791
    CrossrefPubMedGoogle Scholar
  • 3 Cortés J, Kim S-B, Chung W-P. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022; 386: 1143-1154
    CrossrefPubMedGoogle Scholar
  • 4 Modi S, Saura C, Yamashita T. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020; 382: 610-621
    CrossrefPubMedGoogle Scholar
  • 5 Rugo HS, Bardia A, Marmé F. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1423-1433
    CrossrefPubMedGoogle Scholar
  • 6 Bardia A, Hurvitz SA, Tolaney SM. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021; 384: 1529-1541
    CrossrefPubMedGoogle Scholar
  • 7 Cortes J, Cescon DW, Rugo HS. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817-1828
    CrossrefPubMedGoogle Scholar
  • 8 Cortes J, Rugo HS, Cescon DW. et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022; 387: 217-226
    CrossrefPubMedGoogle Scholar
  • 9 Rugo HS, Loi S, Adams S. et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Ann Oncol 2019; 30: v858-v859
    CrossrefPubMedGoogle Scholar
  • 10 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379: 2108-2121
    CrossrefPubMedGoogle Scholar
  • 11 Schmid P, Rugo HS, Adams S. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 44-59
    CrossrefPubMedGoogle Scholar
  • 12 Miles D, Gligorov J, André F. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 2021; 32: 994-1004
    CrossrefPubMedGoogle Scholar
  • 13 Schneeweiss A, Brucker SY, Hübner HC. et al. CDK4/6 Inhibition – Therapy Sequences and the Quest for Finding the Best Biomarkers – an Overview of Current Programs. Geburtshilfe Frauenheilkd 2024; DOI: 10.1055/a-2286-6066.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Nabieva N, Fasching PA. CDK4/6 Inhibitors–Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers 2023; 15: 1763
    CrossrefPubMedGoogle Scholar
  • 15 Turner NC, Oliveira M, Howell SJ. et al. Capivasertib in hormone receptor–positive advanced breast cancer. N Engl J Med 2023; 388: 2058-2070
    CrossrefPubMedGoogle Scholar
  • 16 Jhaveri K, Im S-A, Saura C. et al. Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III, INAVO120 primary analysis. Proceedings of the 2023 San Antonio Breast Cancer Symposium, San Antonio, TX, USA 2023; 2023: 5-9
    PubMedGoogle Scholar
  • 17 Litton JK, Rugo HS, Ettl J. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018; 379: 753-763
    CrossrefPubMedGoogle Scholar
  • 18 Turner NC, Telli ML, Rugo HS. et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res 2019; 25: 2717-2724
    CrossrefPubMedGoogle Scholar
  • 19 Hurvitz S, Quek R, Turner N. et al. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. Eur J Cancer 2018; 104: 160-168
    CrossrefPubMedGoogle Scholar
  • 20 Robson M, Im S-A, Senkus E. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523-533
    CrossrefPubMedGoogle Scholar
  • 21 Ettl J, Quek R, Lee K-H. et al. Quality of life with talazoparib versus physicianʼs choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 2018; 29: 1939-1947
    CrossrefPubMedGoogle Scholar
  • 22 Robson M, Ruddy KJ, Seock-Ah I. et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer 2019; 120: 20-30
    CrossrefPubMedGoogle Scholar
  • 23 Engler T, Fasching PA, Lüftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients–Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022; 82: 1055-1067
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Braun MSO, Salat C. et al. Current therapy landscape of advanced HER2 negative breast cancer in pateints in a network of office based internistic oncologists and gynecologic oncologists in Germany. Deutscher Krebskongress 2022; 2022: Abstr.. 306
    PubMedGoogle Scholar
  • 25 AGO Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome: Therapiealgorithmen. 2024 Online (Stand: 25.03.2024): https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
    PubMedGoogle Scholar
  • 26 Cardoso F, Paluch-Shimon S, Senkus E. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC5). Ann Oncol 2020; 31: 1623-1649
    CrossrefPubMedGoogle Scholar
  • 27 Lu Y-S, Mahidin EIBM, Azim H. et al. Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Presented at SABCS 2022. December 6–10, 2022. Abstract GS1-10.
    PubMedGoogle Scholar
  • 28 Ma H, Lu Y, Marchbanks PA. et al. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res 2013; 15: 1-12
    CrossrefPubMedGoogle Scholar
  • 29 Azim H, El Saghir N, Yap Y. et al. 402P First-line ribociclib (RIB)+ endocrine therapy (ET) vs. combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study. Ann Oncol 2023; 34: S350-S351
    CrossrefPubMedGoogle Scholar
  • 30 Schneeweiss A, Ettl J, Lüftner D. et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer–Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88-95
    CrossrefPubMedGoogle Scholar
  • 31 Fasching PA, Yadav S, Hu C. et al. Mutations in BRCA1/2 and other panel genes in patients with metastatic breast cancer–Association with patient and disease characteristics and effect on prognosis. J Clin Oncol 2021; 39: 1619
    CrossrefPubMedGoogle Scholar
  • 32 Hartkopf AD, Huober J, Volz B. et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors–Data from the German PRAEGNANT breast cancer registry. Breast 2018; 37: 42-51
    CrossrefPubMedGoogle Scholar
  • 33 Sonke GS, Van Ommen-Nijhof A, Wortelboer N. et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). JCO 2023; 41 (Suppl.) LBA1000 DOI: 10.1200/JCO.2023.41.17_suppl.LBA1000.
    CrossrefPubMedGoogle Scholar
  • 34 Finn RS, Rugo HS, Dieras VC. et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. JCO 2022; 40 (Suppl.) LBA1003 DOI: 10.1200/JCO.2022.40.17_suppl.LBA1003.
    CrossrefPubMedGoogle Scholar
  • 35 Kalinsky K, Accordino MK, Chiuzan C. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: Maintain trial. J Clin Oncol 2023; 41: 4004-4013
    CrossrefPubMedGoogle Scholar
  • 36 Mayer EL, Ren Y, Wagle N. et al. Abstract Gs3-06: Gs3-06 Palbociclib after Cdk4/6I and endocrine therapy (PACE): A randomized phase II study of Fulvestrant, Palbociclib, and Avelumab for endocrine pre-treated ER+/Her2-metastatic breast cancer. Cancer Res 2023; 83(5_Supplement): GS3-06
    CrossrefPubMedGoogle Scholar
  • 37 Bidard F-C, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 2022; 40: 3246
    CrossrefPubMedGoogle Scholar
  • 38 Clinicaltrials.gov. Study of Trastuzumab Deruxtecan (T-DXd) vs. Investigatorʼs Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06). 2024 Online (Stand: 24.01.2024): https://clinicaltrials.gov/study/NCT04494425
    PubMedGoogle Scholar
  • 39 Modi S, Jacot W, Yamashita T. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022; 387: 9-20
    CrossrefPubMedGoogle Scholar
  • 40 Bardia A, Jhaveri K, Im S. et al. LBA11 Datopotamab deruxtecan (Dato-DXd) vs. chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. Ann Oncol 2023; 34: S1264-S1265
    CrossrefPubMedGoogle Scholar
  • 41 Murthy RK, Loi S, Okines A. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020; 382: 597-609
    CrossrefPubMedGoogle Scholar
  • 42 Curigliano G, Mueller V, Borges V. et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol 2022; 33: 321-329
    CrossrefPubMedGoogle Scholar
  • 43 Hurvitz S, Modi S, Li W. et al. 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03. Ann Oncol 2023; 34: S335-S336
    CrossrefPubMedGoogle Scholar
  • 44 Miglietta F, Visani L, Marini S. et al. Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?. Cancer Treat Rev 2022; 110: 102462
    CrossrefPubMedGoogle Scholar
  • 45 Palma DA, Olson R, Harrow S. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 2020; 38: 2830
    CrossrefPubMedGoogle Scholar
  • 46 Chmura SJ, Winter KA, Woodward WA. et al. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). JCO 2022; 40 (Suppl.) 1007 DOI: 10.1200/JCO.2022.40.16_suppl.1007.
    CrossrefPubMedGoogle Scholar
  • 47 Müller V, Hein A, Hartkopf AD. et al. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics–A retrospective analysis of a real world registry. Eur J Cancer 2022; 172: 13-21
    CrossrefPubMedGoogle Scholar
  • 48 Caglevic C, Rolfo C, Gil-Bazo I. et al. The armed conflict and the impact on patients with cancer in Ukraine: Urgent considerations. JCO Glob Oncol 2022; 8: e2200123
    CrossrefPubMedGoogle Scholar
  • 49 van Leeuwen RW, Jansman FG, van den Bemt PM. et al. Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 2015; 26: 992-997
    CrossrefPubMedGoogle Scholar
  • 50 Poggio F, Tagliamento M, Pirrone C. et al. Update on the management of breast cancer during pregnancy. Cancers 2020; 12: 3616
    CrossrefPubMedGoogle Scholar
  • 51 Loibl S, Han SN, von Minckwitz G. et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012; 13: 887-896
    CrossrefPubMedGoogle Scholar
  • 52 Amant F, von Minckwitz G, Han SN. et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol 2013; 31: 2532-2539
    CrossrefPubMedGoogle Scholar
  • 53 Loibl S, Schmidt A, Gentilini O. et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol 2015; 1: 1145-1153
    CrossrefPubMedGoogle Scholar
  • 54 Khan SA, Zhao F, Solin LJ. et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol 2020; 38(Suppl): LBA2 DOI: 10.1200/JCO.2020.38.18_suppl.LBA2.
    CrossrefPubMedGoogle Scholar
  • 55 Loibl S, Azim jr. HA, Bachelot T. et al. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC). Ann Oncol 2023; 34: 849-866
    CrossrefPubMedGoogle Scholar